PEACCEL

#Quantum biologics discovery in healthcare can save many lives. We're thrilled to announce #PEACCEL's pioneering paper in the realm of Quantum Computing for biologics, marking a significant leap forward in pharmaceutical discovery. Our cutting-edge research, conducted in collaboration with the University of Western Australia's esteemed Quantum Physics and Computing team - Shengxin Zhuang, John Tanner, Yusen Wu, under the great leadership of Prof Jingbo Wang, Ass. Prof Du Huynh, and Ass. Prof Weil Liu - demonstrates the untapped potential of Quantum Machine Learning (QML) in the biopharmaceutical industry. 🌐 Quantum Advantages in Computational Biology 🌐 This research underlines the significant, yet largely untapped, advantages of quantum computing in the field of computational biology. By demonstrating that QSVM can exceed the performance of classical machine learning models, we provide empirical evidence and hope for quantum advantages in real-world applications, particularly in developing safer therapeutic solutions. 🔬 Why This Matters for Pharma 🔬 In our study, we applied the quantum support vector machine (QSVM, up to 14 Qubits) to a crucial task: classifying peptides as either hemolytic or non-hemolytic. According to the French national health database, 160 drugs have been shown to induce autoimmune hemolytic anemia for the period 2012-2018, and 3,371 cases of Drug Induce Autoimmune Hemolytic anemia (DI-AIHA) were recorded (https://lnkd.in/gpmyP3ee). 1% wrong class assignment means more human deaths by hemolysis. A 1% gain in accuracy in healthcare can save many lives. The implications of this work for the pharmaceutical industry are profound. We can harness the quantum leap to expedite the development of novel biologics and transform patient care worldwide.   For more information: https://lnkd.in/gqy2sPMQ #QuantumComputing #Biologics #Pharmaceuticals #artificialintelligence #DrugDiscovery

#Quantum biologics discovery in healthcare can save many lives. We're thrilled to announce #PEACCEL's pioneering paper in the realm of Quantum Computing for biologics, marking a significant leap forward in pharmaceutical discovery. Our cutting-edge research, conducted in collaboration with the University of Western Australia's esteemed Quantum Physics and Computing team - Shengxin Zhuang, John Tanner, Yusen Wu, under the great leadership of Prof Jingbo Wang, Ass. Prof Du Huynh, and Ass. Prof Weil Liu - demonstrates the untapped potential of Quantum Machine Learning (QML) in the biopharmaceutical industry. 🌐 Quantum Advantages in Computational Biology 🌐 This research underlines the significant, yet largely untapped, advantages of quantum computing in the field of computational biology. By demonstrating that QSVM can exceed the performance of classical machine learning models, we provide empirical evidence and hope for quantum advantages in real-world applications, particularly in developing safer therapeutic solutions. 🔬 Why This Matters for Pharma 🔬 In our study, we applied the quantum support vector machine (QSVM, up to 14 Qubits) to a crucial task: classifying peptides as either hemolytic or non-hemolytic. According to the French national health database, 160 drugs have been shown to induce autoimmune hemolytic anemia for the period 2012-2018, and 3,371 cases of Drug Induce Autoimmune Hemolytic anemia (DI-AIHA) were recorded (https://lnkd.in/gpmyP3ee). 1% wrong class assignment means more human deaths by hemolysis. A 1% gain in accuracy in healthcare can save many lives. The implications of this work for the pharmaceutical industry are profound. We can harness the quantum leap to expedite the development of novel biologics and transform patient care worldwide.   For more information: https://lnkd.in/gqy2sPMQ #QuantumComputing #Biologics #Pharmaceuticals #artificialintelligence #DrugDiscovery

#Quantum biologics discovery in healthcare can save many lives. We're thrilled to announce #PEACCEL's pioneering paper in the realm of Quantum Computing for biologics, marking a significant leap forward in pharmaceutical discovery. Our cutting-edge research, conducted in collaboration with the University of Western Australia's esteemed Quantum Physics and Computing team - Shengxin Zhuang, John Tanner, Yusen Wu, under the great leadership of Prof Jingbo Wang, Ass. Prof Du Huynh, and Ass. Prof Weil Liu - demonstrates the untapped potential of Quantum Machine Learning (QML) in the biopharmaceutical industry. 🌐 Quantum Advantages in Computational Biology 🌐 This research underlines the significant, yet largely untapped, advantages of quantum computing in the field of computational biology. By demonstrating that QSVM can exceed the performance of classical machine learning models, we provide empirical evidence and hope for quantum advantages in real-world applications, particularly in developing safer therapeutic solutions. 🔬 Why This Matters for Pharma 🔬 In our study, we applied the quantum support vector machine (QSVM, up to 14 Qubits) to a crucial task: classifying peptides as either hemolytic or non-hemolytic. According to the French national health database, 160 drugs have been shown to induce autoimmune hemolytic anemia for the period 2012-2018, and 3,371 cases of Drug Induce Autoimmune Hemolytic anemia (DI-AIHA) were recorded (https://lnkd.in/gpmyP3ee). 1% wrong class assignment means more human deaths by hemolysis. A 1% gain in accuracy in healthcare can save many lives. The implications of this work for the pharmaceutical industry are profound. We can harness the quantum leap to expedite the development of novel biologics and transform patient care worldwide.   For more information: https://lnkd.in/gqy2sPMQ #QuantumComputing #Biologics #Pharmaceuticals #artificialintelligence #DrugDiscovery

We're thrilled to share an exciting milestone at PEACCEL - our disruptive AI discovery platform for biologics is setting new benchmarks in the pharmaceutical industry. By unlocking previously inaccessible spaces, we are identifying novel, life-changing drugs that were only possible in nature 1% of the time. Imagine the potential when we can screen 1 billion molecules in a single day! 🌐 A Game-Changing Collaboration: PEACCEL & Google Cloud 🌐 Our journey has taken an exhilarating turn as we were handpicked to join the Google Startup Program. This collaboration is not just an endorsement of our innovative approach; it's a catalyst for exponential growth and impact. Here's what this means for the pharmaceutical industry: 1. Massive Scale Screening: From millions to over a billion molecules per day, pushing the boundaries of drug candidate identification from good to the BEST. 2. Industrial Scale AI: Our platform's scalability is now supercharged, ready for real-world applications at an industrial level. 3. Unprecedented Computing Power: Access to a vast array of GPUs, expanding our computing capacity to accelerate drug development, reduce costs, and bring life-saving treatments to market faster. 4. Robust Infrastructure & Tools: Leveraging Google's state-of-the-art technology to enhance our research capabilities, foster innovation and drive forward the future of drug discovery. 🔍 Why Does This Matter? This represents a unique opportunity to be at the forefront of AI-driven biologics discovery. PEACCEL is not just advancing drug discovery; we are redefining it. By joining forces with Google Cloud, we are ensuring that our platform is not only groundbreaking but also scalable and accessible for pharmaceutical companies aiming to transition from good to groundbreaking drug candidates. 💡 Join Us in Shaping the Future. We are on the brink of revolutionizing the pharmaceutical industry and invite VCs who share our vision of creating life-changing drugs through AI and biologics to join us on this exciting journey. Let's innovate and impact lives together. Reach out to learn more about how you can be part of this transformative venture. Read more: https://lnkd.in/dkS-cPF4 #DeepTech #aidrugdiscovery #pharmaceuticals #biologics #venturecapital

We are thrilled to announce that PEACCEL has been awarded the prestigious French DeepTech label by BPI France, the public investment bank dedicated to innovation. This recognition is a testament to our commitment to pushing the boundaries of biotechnology with our groundbreaking AI discovery platform for Biologics. 🔍 Our Platform's Impact: PEACCEL's AI-driven platform is transforming the pharmaceutical industry by enabling access to previously inaccessible spaces for drug discovery. Our technology makes it possible to identify novel, life-changing drugs by replicating processes that occur in nature only 1% of the time. This opens up new horizons in the quest for groundbreaking treatments. 💡 Why This Matters for VCs: PEACCEL's recognition by BPI France underscores our high quality and potential. With the DeepTech label, we gain easier access to public funding up to €15 million, alongside personalized support for our development. This is an unparalleled opportunity for venture capital investors looking to be part of a high-potential, innovative journey in the biotech space. We are on the brink of revolutionizing the pharmaceutical industry and invite VCs who share our vision of creating life-changing drugs through AI and biologics to join us on this exciting journey. Let's innovate and impact lives together. Reach out to learn more about how you can be part of this transformative venture. 🏅 About the French DeepTech Label: The DeepTech label from BPI France is reserved for companies that demonstrate strong growth potential and possess disruptive technologies. To be recognized, a company must innovate by overcoming technological barriers and present a significantly differentiating advantage over competitors. Read more…  https://lnkd.in/gd3gBPvY #DeepTech #venturecapital #aidrugdiscovery #pharmaceuticals #biologics

Impressive achievement Sia Partners and Latham BioPharm Group, part of Sia Partners teams!